Clinical trial
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of…
NCT00106535 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00106535 |
|---|---|
| Title | A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) |
| Official title | A Randomized, Double-blind Study of Safety and Prevention of Structural Joint Damage During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | tocilizumab [RoActemra/Actemra], Placebo, Methotrexate |
| Enrollment | 1,196 |
| Start date | Jan 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | Jul 1, 2012 |
| First posted | Mar 28, 2005 |
| Last update posted | Feb 6, 2014 |
| Countries | Australia, Brazil, China, Denmark, Finland, France, Greece, Italy, Mexico, Norway, Poland, Puerto Rico and 4 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: